Fundraising FoxRock Springs Capital — 2019 Investments
4 investments dated 2019 · listed companies and verified rows first · show all
Imara is a clinical-stage biopharmaceutical company developing small molecule therapeutics for unmet medical needs, currently advancing ELVN-001, a selective kinase inhibitor designed to treat chronic myeloid leukemia by targeting the BCR-ABL gene fusion.
BiotechCambridge, US
James G. McArthur(Executive Officer, Director)Christoph M. Adams(Executive Officer, Director)Richard Fair(President, Chief Executive Officer, Director)
BoardSara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)
Co-investorsBay City CapitalNew Enterprise Associates (NEA)RA CapitalAlexandriaArix BioscienceLundbeckfonden Ventures+2 more
Fusion Pharma develops targeted alpha therapeutics that link alpha-emitting medical isotopes to molecules targeting biomarkers on cancer cell surfaces to selectively kill tumor cells.
BiotechHealthtech
John Valliant(Founder)in
Co-investorsFACIT (Fight Against Cancer Innovation Trust)HealthCapLumira VenturesPivotal Life SciencesSeroba Life SciencesVenture Ontario+6 more
This page is a news post from Azafaros, a biopharmaceutical company developing disease-modifying therapeutics for lysosomal storage disorders with a focus on neurological symptoms.
Biotech
Co-investorsCDP Venture CapitalIreland Strategic Investment FundAdams Street PartnersGenesys CapitalHealthCapOrbiMed+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.